**Supplementary Table 1. Baseline characteristics of the treatment group and control group**

|  |  |  |  |
| --- | --- | --- | --- |
| Characteristics | Treatment group (n = 197) | IHC control group (n = 221) | *p*-value |
| Male (%) | 134(68.0) | 142(64.3) | 0.469 |
| Age, years, mean ±SD | 38.0±10.2 | 37.0±10.7 | 0.294 |
| BMI, kg/cm2, mean ±SD | 22.5±1.2 | 22.9±1.0 | 0.349 |
| Mode of transmission |  |  |  |
| Vertical (%)† | 107(54.3) | 133(60.2) | 0.236 |
| Others (%)‡ | 90(45.7) | 88(39.8) |  |
| HBsAg at baseline |  |  |  |
| < 100 IU/mL (%) | 79(40.1) | 72(32.6) | 0.189 |
| 100-500 IU/mL (%) | 45(22.8) | 65(29.4) |  |
| 500-1500 IU/mL (%) | 73(37.1) | 84(38.0) |  |
| HBV DNA at week 0 |  |  |  |
| <20 IU/mL (%) | 66(33.5) | 82(37.1) | 0.474 |
| 20- 2000 IU/mL (%) | 131(66.5) | 139(62.9) |  |
| Genotype |  |  | 0.413 |
| A | 6(3.0) | 10(4.5) |  |
| B | 17(8.6) | 11(5.0) |  |
| C | 21(10.7) | 28(12.7) |  |
| D | 4(2.0) | 8(3.6) |  |
| Undetectable | 149(75.6) | 164(74.2) |  |
| ALT, IU/L, median (Q1, Q3) | 23.0(16.0, 32.0) | 24.0(17.0, 33.0) | 0.608 |
| AST, IU/L, median (Q1, Q3) | 24.0(20.0, 30.0) | 26.0(21.0, 32.0) | 0.077 |
| LSM, kPa, median (Q1, Q3) | 4.8(3.8, 6.2) | 5.0(4.1, 6.6) | 0.125 |
| < 9.0 kPa, n (%) | 158(80.2) | 174(78.7) | 0.718 |
| 9.0-12.0 kPa, n (%) | 39(19.8) | 47(21.3) |  |
| Treatment  |  |  |  |
| Peg-IFNα-2a (%) | 50(25.4) | - | - |
| Peg-IFNα-2b (%) | 147(74.6) | - |  |

†Participants whose mothers had a clear history of chronic HBV infection. ‡Participants whose mothers had no clear history of chronic HBV infection or whose history of chronic HBV infection was unclear. SD, standard deviation; BMI, body mass index; HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B e antigen; HBV DNA, hepatitis B virus deoxyribonucleic acid; ALT, alanine aminotransferase; LSM, liver stiffness measurement.